Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging

Cancers

Shin Yaogawa²  Yasuhiro Ogawa³  Shiho Morita-Tokuhiro²  Akira Tsuzuki²  Ryo Akima²  Kenji Itoh¹  Kazuo Morio¹  Hiroaki Yasunami¹  Masahide Onogawa⁴  Shinji Kariya²  Munenobu Nogami²  Akihito Nishioka²  Mitsuhiko Miyamura⁴  Zhe-Sheng (Jason) Chen⁵ 

[1] Division of Radiology, Medical School Hospital, Kochi University, Nankoku, Kochi 783-8505, Japan;Department of Diagnostic Radiology & Radiation Oncology, Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan;;Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo 675-8555, JapanDepartment of Pharmacy, Medical School Hospital, Kochi University, Nankoku, Kochi 783-8505, Japan;;Department of Diagnostic Radiology & Radiation Oncology, Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan

关键词: MRI;    breast cancer;    KORTUC;    hydrogen peroxide;    radiosensitizer;    sodium hyaluronate;   

DOI  :  10.3390/cancers8010001

来源: mdpi

【 摘 要 】

Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.